Home Telemonitoring and a Diagnostic Algorithm in the Management of Heart Failure in the Netherlands: Cost-effectiveness Analysis

Autor: Fernando Albuquerque de Almeida, Isaac Corro Ramos, Maiwenn Al, Maureen Rutten-van Mölken

Publikováno v: JMIR Cardio, Vol 6, Iss 2, p e31302 (2022)

BackgroundHeart failure is a major health concern associated with significant morbidity, mortality, and reduced quality of life in patients. Home telemonitoring (HTM) facilitates frequent or continuous assessment of disease signs and symptoms, and it

Externí odkaz: https://doaj.org/article/3f25ee0520e44bdc9ceb831ac56131e6

Biologicals and Biosimilars: Gaps in the Pharmacovigilance System in Portugal

Autor: Maria da Conceição Constantino Portela, Carlos Sinogas, Fernando Albuquerque de Almeida, Ricardo Baptista-Leite, Alexandre Castro-Caldas

Publikováno v: Acta Médica Portuguesa, Vol 30, Iss 3, Pp 205-212 (2017)

Introduction: Biological and biosimilar medicinal products have specific characteristics that call for a closer monitoring of their safety profile. Since the current legal framework stems from both European and national regulations, some gaps in the

Externí odkaz: https://doaj.org/article/fd8d267f551248d6b2c4a2338278eb8b

Matching-Adjusted Indirect Comparisons of Lorlatinib Versus Chemotherapy for Patients With Second-Line or Later Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer

Autor: Sarah Smith, Fernando Albuquerque de Almeida, Monica Inês, Laura Iadeluca, Miranda Cooper

Publikováno v: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

This study aimed to compare the relative efficacy of lorlatinib, an anaplastic lymphoma kinase-tyrosine kinase inhibitor, with chemotherapy, for patients with second-line or later advanced anaplastic lymphoma kinase-positive non-small cell lung cance

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::545b9ce100c31f6f3ed91a5e1e10208b
https://pubmed.ncbi.nlm.nih.gov/35985941

Impact of hospitalisation on health-related quality of life in patients with chronic heart failure

Autor: Maiwenn Al, Ron Koymans, Jarno Riistama, Steffen Pauws, Johan L. Severens, Fernando Albuquerque de Almeida

Publikováno v: Health and Quality of Life Outcomes, 18(1):262, 1-10. BioMed Central Ltd.
Health and Quality of Life Outcomes, Vol 18, Iss 1, Pp 1-10 (2020)
Health and Quality of Life Outcomes, 18(1):262. BioMed Central Ltd.
Health and Quality of Life Outcomes

Background Empirical identification of the direct impact of hospitalisation in the change in utility could provide an interpretation for some of the unexplained variance in quality of life responses in clinical practice and clinical trials and provid

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cbd34ebc07c37da8d2f343e4410087e
https://research.tilburguniversity.edu/en/publications/6ad3c0b7-0b5f-458f-981f-37d79cc0cee0

Biologicals and biosimilars: safety issues in Europe

Autor: Maria da Conceição Constantino Portela, Ricardo Baptista-Leite, Fernando Albuquerque de Almeida, Carlos Sinogas, Alexandre Castro-Caldas

Publikováno v: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Agência para a Sociedade do Conhecimento (UMIC)-FCT-Sociedade da Informação
instacron:RCAAP

Introduction: Medicinal products of a biological origin are approved by the EMA at a centralized level. However, there is no harmonization about their use in Europe. The current regulation referring to the safety of biological medicinal products and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::156a5da13654024a6ae275685b21811e
https://doi.org/10.1080/14712598.2017.1330409